8 June, 2024

EU Pharmaceutical Legislation Reform

The EU’s overhaul of pharmaceutical legislation signals a pivotal shift for companies navigating regulatory data protection (RDP) and market exclusivity. This reform aims to balance patient access with innovation, introducing shorter data protection periods with possible extensions for incentivized innovation, keeping the EU competitive with U.S. and Japanese models.

This article explores the key changes, covering impacts on R&D, clinical trials, and market strategies, and outlines the strategic adjustments necessary to thrive in an evolving regulatory landscape.

Please enter your details to get access to the content









    Discover how we can help you

    Close Popup

    This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

    Close Popup
    Privacy Settings saved!
    Privacy Settings

    When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

    These cookies are necessary for the website to function and cannot be switched off in our systems.

    Technical Cookies
    In order to use this website we use the following technically required cookies
    • wordpress_test_cookie
    • wordpress_logged_in_
    • wordpress_sec

    Cloudflare
    In order to use this website we use the following technically required cookies
    • __cfduid

    Decline all Services
    Save
    Accept all Services